KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Finished Goods: 2018-2020

  • Amneal Pharmaceuticals' Finished Goods was N/A to $222.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $222.2 million, marking a year-over-year change of. This contributed to the annual value of $150.7 million for FY2019, which is 31.93% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Finished Goods stood at $222.2 million for Q1 2020, which was up 47.40% from $150.7 million recorded in Q4 2019.
  • Over the past 5 years, Amneal Pharmaceuticals' Finished Goods peaked at $222.2 million during Q1 2020, and registered a low of $150.7 million during Q4 2019.
  • Its 3-year average for Finished Goods is $190.6 million, with a median of $194.8 million in 2018.
  • Data for Amneal Pharmaceuticals' Finished Goods shows a maximum YoY tumbled of 31.93% (in 2019) over the last 5 years.
  • Quarterly analysis of 3 years shows Amneal Pharmaceuticals' Finished Goods stood at $221.4 million in 2018, then plummeted by 31.93% to $150.7 million in 2019, then reached $222.2 million in 2020.
  • Its Finished Goods was $222.2 million in Q1 2020, compared to $150.7 million in Q4 2019 and $168.2 million in Q3 2019.